» Articles » PMID: 34319042

Early Diagnosis of Oral Squamous Cell Carcinoma (OSCC) by MiR-138 and MiR-424-5p Expression As a Cancer Marker

Overview
Specialty Oncology
Date 2021 Jul 28
PMID 34319042
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: MicroRNAs (miRs) are a group of endogenous, non-coding, 18-24 nucleotide length single-strand RNAs. These molecules mediate the gene expression and are involved in regulating diverse cellular biological processes, i.e. cell cycle, differentiation, and apoptosis. Aberrant miR expression has been shown to be an important event in the pathologies of various types of cancer, including oral squamous cell carcinoma (OSCC).

Methods: Blood samples were obtained from 30 patients (15 cases and 15 controls), to determine miR-138 and miR-424-5p expression by using real-time PCR and ΔΔCT.

Results: The median CT values of miR-138 were 27.60 and 28.70, while those of miR 424-5p were 29.40 and 30.0 in the case and control groups, respectively. Mann-Whitney test indicated no significant difference in miR-138 and miR-424-5p between the two groups (P > 0.05). However, results obtained by ΔΔCT method showed that miR-424-5p expression was 1.96 times higher in the case group, but miR-138 expression was 3.05 times lower in the plasma of OSCC patients.

Conclusion: Our findings suggest that the evaluation of miR-138 and miR-424-5p expression in serum can be used as potent markers for carcinoma detection and also may be a potentially therapeutic approach in the future. Further longitudinal studies with larger samples are required to verify these findings.<br />.

Citing Articles

Expression Analysis of Circulating microRNAs in Saliva and Plasma for the Identification of Clinically Relevant Biomarkers for Oral Squamous Cell Carcinoma and Oral Potentially Malignant Disorders.

Rocchetti F, Tenore G, Macali F, Vicidomini T, Podda G, Fantozzi P Cancers (Basel). 2024; 16(17).

PMID: 39272848 PMC: 11394426. DOI: 10.3390/cancers16172990.


Biomarkers for Oral Squamous Cell Carcinoma (miR-24, miR-200, and miR-34): Screening and Detection MicroRNA.

Bahrami N, Pirrafiee M, Azadi F, Azimnejad R, Fotook Kiaei S, Abbasi A Asian Pac J Cancer Prev. 2024; 25(7):2265-2269.

PMID: 39068557 PMC: 11480605. DOI: 10.31557/APJCP.2024.25.7.2265.


Oral Squamous Cell Carcinoma: Focus on Biomarkers for Screening.

Ghaderi H, Roshan-Zamir M, Jafarinia M, Kruger E J Dent (Shiraz). 2024; 25(1):1-16.

PMID: 38544776 PMC: 10963865. DOI: 10.30476/dentjods.2023.96159.1924.


Evaluation of immuno-histochemical markers in oral squamous cell carcinoma.

Guruprasad Y, Singhal P, Gupta N, Kukreja B, Gupta B, Kukreja P Bioinformation. 2024; 19(13):1399-1404.

PMID: 38415034 PMC: 10895524. DOI: 10.6026/973206300191399.


Oral squamous cell carcinomas: state of the field and emerging directions.

Tan Y, Wang Z, Xu M, Li B, Huang Z, Qin S Int J Oral Sci. 2023; 15(1):44.

PMID: 37736748 PMC: 10517027. DOI: 10.1038/s41368-023-00249-w.


References
1.
Jansson M, Lund A . MicroRNA and cancer. Mol Oncol. 2012; 6(6):590-610. PMC: 5528350. DOI: 10.1016/j.molonc.2012.09.006. View

2.
Singh P, Srivastava A, Sharma R, Mateen S, Shukla B, Singh A . Circulating MicroRNA-21 Expression as a Novel Serum Biomarker for Oral Sub-Mucous Fibrosis and Oral Squamous Cell Carcinoma. Asian Pac J Cancer Prev. 2018; 19(4):1053-1057. PMC: 6031776. DOI: 10.22034/APJCP.2018.19.4.1053. View

3.
Shan X, Zhang H, Zhang L, Zhou X, Wang T, Zhang J . Identification of four plasma microRNAs as potential biomarkers in the diagnosis of male lung squamous cell carcinoma patients in China. Cancer Med. 2018; 7(6):2370-2381. PMC: 6010830. DOI: 10.1002/cam4.1490. View

4.
Zeljic K, Jovanovic I, Jovanovic J, Magic Z, Stankovic A, Supic G . MicroRNA meta-signature of oral cancer: evidence from a meta-analysis. Ups J Med Sci. 2018; 123(1):43-49. PMC: 5901467. DOI: 10.1080/03009734.2018.1439551. View

5.
Wang K, Chen D, Meng Y, Xu J, Zhang Q . Clinical evaluation of 4 types of microRNA in serum as biomarkers of esophageal squamous cell carcinoma. Oncol Lett. 2018; 16(1):1196-1204. PMC: 6019944. DOI: 10.3892/ol.2018.8720. View